Catheter Ablation as Treatment for Atrial Fibrillation
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria, indications, repeat procedure policy, investigational exclusions, and procedural context for transcatheter radiofrequency, cryoablation, and pulsed field ablation to treat atrial fibrillation for BCBSKS members. Applies to symptomatic paroxysmal or persistent AF, AF with heart failure as an alternative to AV nodal ablation/pacing, initial therapy in recurrent symptomatic paroxysmal AF, and repeat procedures.
Update dated 04-23-2025: policy section and rationale updated to include pulse field ablation alongside radiofrequency and cryoablation.
Multiple historical liberalizations to require resistance to one or more antiarrhythmic drugs rather than two or more.
CPT code updates over time (added 93655, 93656, 93657; removed older codes).
Coverage summary
This policy covers transcatheter catheter ablation (radiofrequency ablation, cryoablation, and pulsed field ablation (PFA)) for treatment of atrial fibrillation. It applies to BCBSKS members with symptomatic paroxysmal or persistent AF who have failed adequate trials of antiarrhythmic medications (or have intolerance/contraindication), to selected individuals with AF and class II–III congestive heart failure as an alternative to AV nodal ablation and pacemaker insertion, and as an initial rhythm-control option for recurrent symptomatic paroxysmal AF when rhythm control is desired. Repeat ablation (RFA, cryo, or PFA) is covered when there is recurrence of AF and/or development of atrial flutter after the initial procedure. Procedures that do not meet the listed criteria are considered experimental/investigational and not medically necessary. The policy reflects device- and modality-neutral coverage across RFA, cryoablation, and PFA and notes that pulmonary vein isolation is the cornerstone of most procedures. Last review date: 2024-12-09; policy update adding PFA to policy statements dated 04-23-2025.
Medical necessity — criteria
Medically Necessary Indications
Transcatheter radiofrequency ablation, cryoablation or pulse field ablation may be considered medically necessary when ALL of the following for an indication are met:
Indications (ANY of the following)
- Symptomatic paroxysmal or symptomatic persistent atrial fibrillation that has failed to respond to adequate trials of antiarrhythmic medications, or the individual has intolerance of or a contraindication to appropriate antiarrhythmic medications
- As an alternative to atrioventricular nodal ablation and pacemaker insertion in individuals with class II or III congestive heart failure and symptomatic atrial fibrillation, who have failed rate control and antiarrhythmic drugs
- As an initial treatment for individuals with recurrent symptomatic paroxysmal atrial fibrillation in whom a rhythm-control strategy is desired
Repeat Procedures
Conditions under which repeat ablation is medically necessary:
- Recurrence of atrial fibrillation and/or development of atrial flutter following the initial procedure
- Provider follows Policy Guidelines regarding repeat procedures (see Policy Guidelines)
Experimental / Investigational (Not Medically Necessary)
Transcatheter ablation is considered experimental / investigational when the case does not meet the criteria above:
Clinical evidence and applicability
Clinical evidence summaries
Study-level findings and conclusions regarding efficacy, safety, and comparative effectiveness
- Repeat procedures: Nonrandomized evidence and an RCT (Pokushalov 2013) suggest repeat ablation increases 1-year maintenance of sinus rhythm versus antiarrhythmic drugs; variability exists in timing and thresholds for repeat procedures.
- RFA vs drug therapy (paroxysmal AF): Multiple RCTs (e.g., Packer 2013; Reddy 2015 contact force RCT) show higher freedom from AF at 1 year with ablation compared with medical therapy; single-procedure success rates vary (example: 57.7% in Packer).
- Cryoablation: RCTs and nonrandomized studies (Packer 2013, Su 2018, Vogt 2013) demonstrate improved freedom from AF at 1 year and up to multi-year follow-up; common complication is phrenic nerve injury (rates variable; often resolves).
- RFA in heart failure: Systematic reviews and RCTs (Zhu 2016; Anselmino 2016; Hunter 2014; Jones 2013; CABANA subgroup Packer 2021) show improvements in LVEF, symptoms, quality of life and some reductions in mortality/composite endpoints in certain trials; AMICA (Kuck 2019) showed no benefit in advanced HF and was stopped for futility.
- First-line ablation (paroxysmal AF): Meta-analyses (Turagam 2021; Elsayed 2021; Hakalathi 2015) and RCTs (RAAFT-2, MANTRA-PAF, EARLY-AF, Cryo-FIRST, STOP-AF) indicate catheter ablation (RFA or cryo) as first-line reduces atrial arrhythmia recurrence and hospitalizations versus antiarrhythmic drugs; specific trials report effect sizes (e.g., EARLY-AF recurrence 42.9% vs 67.8%; Cryo-FIRST freedom 82.2% vs 67.6%).
- Pulsed field ablation (PFA): Reddy et al (2023, ADVENT) randomized PFA vs thermal ablation in treatment-refractory paroxysmal AF and found noninferiority for a composite efficacy endpoint; no significant pulmonary vein stenosis differences observed.
- Complications: Large series and databases report major adverse events in 4%–9%; mortality <1%; tamponade ~1%–3%; vascular access complications up to ~5%; stroke/TIA rates ~0.1%–0.8% in RCTs and up to ~0.6% in some database studies; MRI-detected ischemic lesions common though clinical significance unclear.
- Longer-term follow-up: Freedom from AF declines over years; single-procedure freedom rates vary across studies (examples: Vogt 3-year free after repeat procedures up to ~76.9%; Neumann 5-year single-procedure free ~53%).
Summary of clinical applicability / evidence
PFA considered when meeting population and prior therapy conditions described in RCTs and guidelines:
- Patient has symptomatic paroxysmal or symptomatic persistent atrial fibrillation
- Patient has failed antiarrhythmic drug therapy (resistant to one or more antiarrhythmic drugs) or antiarrhythmic drugs are contraindicated, not tolerated, or not preferred
- Use is consistent with generally accepted medical practice in selected patients per clinical input and guideline statements
Evidence-based findings from randomized controlled trials
PFA compared to thermal ablation in RCTs showed noninferiority for composite effectiveness and similar safety:
- ADVENT trial (Reddy et al., 2023): Paroxysmal AF; PFA noninferior to thermal ablation for composite endpoint (initial procedural failure, documented atrial tachyarrhythmia after 3-month blanking period, antiarrhythmic drug use, cardioversion, or repeat ablation); treatment success at 1 year: PFA 73.3% vs thermal ablation 71.3%; serious AEs PFA 2.4% vs thermal 1.5%.
- SPHERE Per-AF (Anter et al., 2024): Persistent AF (episode duration <1 yr), dual-energy (PFA+RFA) noninferior to RFA for effectiveness and safety; treatment success at 1 year: dual 73.8% vs RFA 65.8%; serious AEs dual 1.4% vs RFA 1.0%.
Limitations and generalizability (from RCTs)
Notable limitations impacting applicability:
- Both RCTs enrolled predominantly White participants (>90%); limited racial/ethnic diversity
- ADVENT excluded persistent AF patients and had minimal reporting of thermal ablation technique (comparator not well-defined)
- Some safety outcomes (e.g., phrenic nerve injury) not included in reported adverse events
- Follow-up duration and other outcome ascertainment limitations noted
Coding and regulatory references
| 93655 | Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, list separately in addition to code for primary procedure |
| 93656 | Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia including 3-dimensional mapping and echocardiography when necessary, with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation |
| 93657 | Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (list separately in addition to code for primary procedure) |
| 93799 | Unlisted cardiovascular service or procedure |
| OAD | FDA product code for RFA catheters (eg, NaviStar ThermoCool) |
| OAE | FDA product code for laser or cryoablation devices (eg, Arctic Front, HeartLight, Freezor Xtra) |
| QZI | FDA product code for pulsed field ablation devices (eg, FARAPULSE, PulseSelect, Sphere-9/Affera systems) |
Prior authorization, documentation & billing
Medical necessity requirement for ablation
Confirm that the patient meets one of the policy's medically necessary indications (symptomatic paroxysmal or persistent AF with failed adequate trials of antiarrhythmic medications or intolerance/contraindication; alternative to AV nodal ablation and pacemaker in class II–III CHF after failed rate control; or initial treatment for recurrent symptomatic paroxysmal AF when a rhythm-control strategy is desired) prior to authorization.
Document prior medical management and indication
Document prior medical management and the clinical indication for ablation, including trials of antiarrhythmic medications and any intolerance or contraindications. For patients with heart failure or when considering ablation as an alternative to AV nodal ablation/pacing, document heart failure class (NYHA) and evidence that rate control failed where applicable. For initial treatment in recurrent symptomatic paroxysmal AF, document that a rhythm-control strategy is desired.
- Trials of one or more antiarrhythmic medications (agents, duration, response)
- Documented intolerance or contraindication to antiarrhythmic drugs, if present
- Heart failure class (NYHA) and LVEF when relevant
- Evidence of failed rate control when claiming alternative to AV nodal ablation/pacing
Repeat procedure coverage
Repeat ablation may be considered medically necessary for documented recurrence of atrial fibrillation or development of atrial flutter following the initial procedure. Ensure documentation of the recurrence and the clinical rationale for the repeat procedure is available as described in the Policy Guidelines.
Evidence of prior medical management or heart failure status
Provide evidence of prior medical management and heart-failure status when applicable. Document prior trials of antiarrhythmic and rate-control therapies and include heart-failure data such as LVEF and NYHA functional class in the record to support medical necessity.
- Prior antiarrhythmic drug therapy (agents, duration, reason for discontinuation)
- Prior rate-control therapy (beta-blocker, calcium channel blocker, digoxin) and response
- LVEF measurement
- NYHA functional class
Blanking period and recurrence reporting
Document the monitoring strategy and timing for detecting recurrence and report recurrences consistent with trial conventions. Note that many trials use a 3-month (90-day) blanking period and define recurrence as atrial tachyarrhythmia/AF episodes lasting >30 seconds after the blanking period.
- Specify monitoring method (ECG, Holter, event monitor, implanted monitor) and schedule
- Document timing relative to the common 3-month/90-day blanking period
- Report recurrence thresholds (commonly >30 seconds)
Clinical indication documentation
Document the clinical indication for the procedure: symptomatic paroxysmal or persistent AF and failure, intolerance, or contraindication to one or more antiarrhythmic drugs, or justification for first-line catheter ablation when selected in accordance with guideline recommendations.
- Symptoms attributable to AF (e.g., palpitations, dyspnea, decreased exercise tolerance)
- Failure/intolerance/contraindication to one or more antiarrhythmic drugs, or guideline-based rationale for first-line ablation
Procedure coding and medical necessity linkage
List of commonly reported CPT codes for AF ablation (informational only). When using these or other procedure codes, ensure the documented procedure and clinical rationale meet the policy's medical necessity criteria and that the codes are linked to that documented medical necessity in the medical record.
Definitions and evidence highlights
Paroxysmal AF: AF episodes lasting less than 7 days and self-terminating.
Persistent AF: AF episodes lasting more than 7 days and can be terminated pharmacologically or by electrical cardioversion.
Blanking period: A prespecified initial post-procedure period (commonly 3 months/90 days) during which arrhythmia recurrences are not counted as treatment failure.
Early recurrence: Recurrence of AF lasting >30 seconds between 3 and 12 months postablation (example used in Andrade 2014).
Treatment success (trial composite): Composite of initial procedural failure, documented atrial tachyarrhythmia after a 3-month blanking period, antiarrhythmic drug use, cardioversion, or repeat ablation.
Revision history
Updated policy section and rationale to add pulsed field ablation alongside radiofrequency and cryoablation; added 'or pulse field ablation' to statements A, B, C and D in the Policy section.
Series of historical revisions reflecting liberalization of prior-therapy thresholds and expansion of policy language: changed requirements to 'resistant to one or more antiarrhythmic drugs' (rather than two or more), added repeat procedure and cryoablation language, and updated policy items A–D accordingly.
Coding section revised: removed CPT 93651 (effective 12-31-2012) and added new CPT codes 93653, 93654, 93655, 93656, 93657 (effective 01-01-2013).
Updated CPT nomenclature to codes 93656 and 93657 and related coding updates.
Coding updates: added CPT code 93655 and removed ICD-9 codes; subsequent coding updates continued in later years.
Revised CPT 93656 descriptor to indicate the service includes 3-dimensional mapping and echocardiography.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.